ERBB2 and breast carcinoma: Health Technology Assessment Report no14. Subcutaneous trastuzumab in the treatment of HER2-positive breast cancer. Final report. March 2021. https://www.argentina.gob.ar/sites/default/files/informe-14-trastuzumab_0.pdf